These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 2354713)
1. Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate. Wagner F; Siefert F; Trenk D; Jähnchen E Eur J Clin Pharmacol; 1990; 38 Suppl 1():S53-9. PubMed ID: 2354713 [TBL] [Abstract][Full Text] [Related]
2. Plasma profile and haemodynamic tolerance to isosorbide-5-mononitrate in controlled-release form. Jähnchen E Br J Clin Pharmacol; 1992; 34 Suppl 1(Suppl 1):15S-17S. PubMed ID: 1633073 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the initial hemodynamic effects of immediate-release versus sustained-release isosorbide-5-mononitrate following single oral doses. Trenk D; Hinder M; Stengele E; Bonn R; Jähnchen E J Clin Pharmacol; 2000 Feb; 40(2):168-76. PubMed ID: 10664923 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. Vogt D; Trenk D; Bonn R; Jähnchen E Eur J Clin Pharmacol; 1994; 46(4):319-24. PubMed ID: 7957516 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). Stockis A; De Bruyn S; Deroubaix X; Jeanbaptiste B; Lebacq E; Nollevaux F; Poli G; Acerbi D Eur J Pharm Biopharm; 2002 Jan; 53(1):49-56. PubMed ID: 11777752 [TBL] [Abstract][Full Text] [Related]
6. Effects of 8:00 a.m. and 2:00 p.m. doses of isosorbide-5-mononitrate during twice-daily therapy in stable angina pectoris. Thadani U; Bittar N Am J Cardiol; 1992 Aug; 70(3):286-92. PubMed ID: 1632390 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics and pharmacodynamics of a new 80 mg oral delayed-action isosorbide dinitrate preparation]. Pello JY; Auclert L; Rey E; Joly H; Mialet C; Puechavy C; Georges M; Ruffo M; Olive G Arch Mal Coeur Vaiss; 1992 Apr; 85 Spec No 1():13-6. PubMed ID: 1530422 [TBL] [Abstract][Full Text] [Related]
13. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. Vree TB; Dammers E; Valducci R Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327 [TBL] [Abstract][Full Text] [Related]
14. Plasma disposition and hemodynamic effects of a single oral dose of isosorbide dinitrate in human males and females. Nakatsu K; Brien JF; Savard G; Toffelmire EB; Abdollah H; Bennett BM; Marks GS Biopharm Drug Dispos; 1992 Jul; 13(5):357-67. PubMed ID: 1498268 [TBL] [Abstract][Full Text] [Related]
15. Lack of tolerance after chronic administration of controlled-release isosorbide-5-mononitrate. Interaction of nitrate and gallopamil. Stauch M; Grossmann G; Wanjura D; Adam WE Eur J Clin Pharmacol; 1990; 38 Suppl 1():S31-4. PubMed ID: 2354712 [TBL] [Abstract][Full Text] [Related]
16. Chronopharmacology of oral nitrates in healthy subjects. Scheidel B; Lemmer B Chronobiol Int; 1991; 8(5):409-19. PubMed ID: 1818789 [TBL] [Abstract][Full Text] [Related]
17. The haemodynamic and anti-ischaemic effects of a single tablet of 80 mg isosorbide dinitrate in slow-release formulation and a review of nitrate tolerance. Silber S; Vogler AC; Krause KH; Theisen K Drugs; 1987; 33 Suppl 4():69-79. PubMed ID: 3622317 [TBL] [Abstract][Full Text] [Related]
18. Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. Mitrovic V; Gessner C; Hain P; Müller KD; Schlepper M Clin Cardiol; 1991 Mar; 14(3):209-18. PubMed ID: 1672843 [TBL] [Abstract][Full Text] [Related]
19. Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. Hutt V; Theodor R; Pabst G; Lutz D; Bonn R; Fritschi E Arzneimittelforschung; 1993 Aug; 43(8):842-6. PubMed ID: 8216439 [TBL] [Abstract][Full Text] [Related]
20. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects. Sundberg S; Lehtonen L Eur J Clin Pharmacol; 2000; 55(11-12):793-9. PubMed ID: 10805056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]